Mirum Pharmaceuticals (NASDAQ:MIRM) Downgraded to Hold Rating by Wall Street Zen

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a report issued on Sunday.

A number of other equities research analysts have also weighed in on the company. JMP Securities boosted their price objective on Mirum Pharmaceuticals from $74.00 to $76.00 and gave the stock a "market outperform" rating in a research report on Friday, May 9th. Raymond James Financial restated a "strong-buy" rating on shares of Mirum Pharmaceuticals in a research report on Tuesday, May 13th. Finally, HC Wainwright restated a "buy" rating and set a $73.00 price objective on shares of Mirum Pharmaceuticals in a research report on Monday, May 19th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $65.50.

Mirum Pharmaceuticals Price Performance

Shares of Mirum Pharmaceuticals stock traded up $3.19 during trading on Friday, reaching $53.46. 703,097 shares of the company's stock were exchanged, compared to its average volume of 462,732. The company has a debt-to-equity ratio of 1.32, a quick ratio of 3.04 and a current ratio of 3.22. Mirum Pharmaceuticals has a 1-year low of $35.63 and a 1-year high of $54.23. The company has a market cap of $2.65 billion, a P/E ratio of -33.20 and a beta of 0.97. The firm's 50-day moving average price is $46.99 and its 200 day moving average price is $45.70.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.30) EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.05. Mirum Pharmaceuticals had a negative return on equity of 33.63% and a negative net margin of 20.39%. The company had revenue of $111.59 million during the quarter, compared to analysts' expectations of $98.47 million. During the same quarter in the previous year, the firm earned ($0.54) EPS. Mirum Pharmaceuticals's revenue was up 61.2% on a year-over-year basis. As a group, research analysts anticipate that Mirum Pharmaceuticals will post -1.43 earnings per share for the current year.

Insider Activity at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 564 shares of the company's stock in a transaction dated Wednesday, July 2nd. The stock was sold at an average price of $48.25, for a total value of $27,213.00. Following the sale, the senior vice president owned 2,903 shares in the company, valued at approximately $140,069.75. The trade was a 16.27% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 14.36% of the company's stock.

Institutional Investors Weigh In On Mirum Pharmaceuticals

A number of institutional investors have recently made changes to their positions in MIRM. CWM LLC grew its position in shares of Mirum Pharmaceuticals by 259.4% in the 1st quarter. CWM LLC now owns 593 shares of the company's stock valued at $27,000 after buying an additional 428 shares during the last quarter. Jones Financial Companies Lllp grew its position in shares of Mirum Pharmaceuticals by 100.0% in the 4th quarter. Jones Financial Companies Lllp now owns 714 shares of the company's stock valued at $30,000 after buying an additional 357 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Mirum Pharmaceuticals in the 4th quarter valued at about $35,000. Comerica Bank boosted its position in shares of Mirum Pharmaceuticals by 45.1% during the 1st quarter. Comerica Bank now owns 895 shares of the company's stock valued at $40,000 after purchasing an additional 278 shares in the last quarter. Finally, GF Fund Management CO. LTD. bought a new stake in shares of Mirum Pharmaceuticals during the 4th quarter valued at about $42,000.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.